Crinetics Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $1.0M | $4.0M | $0 | $0 |
| Operating income | -$516.8M | -$338.9M | -$222.6M | -$167.9M | -$107.7M |
| Operating expenses | — | $339.9M | $226.6M | $172.6M | $108.8M |
| Cost of revenue | $1.1M | $0 | $0 | — | — |
| Cash from operations | -$377.9M | -$230.2M | -$168.6M | -$115.2M | -$88.6M |
| Capital expenditure | $5.8M | $3.8M | $4.7M | $1.7M | $436,000 |
| Free cash flow | -$383.7M | -$234.0M | -$173.3M | -$116.9M | -$89.0M |
| Impairments | — | $0 | $0 | $0 | $0 |
| Total assets | $1.1B | $1.4B | $635.4M | $352.2M | $351.0M |
| Total liabilities | $134.2M | $109.8M | $96.2M | $35.8M | $19.1M |
Shares outstanding 105.4M · Free float 90.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.